Vesilute 20mg
Bladder Tissue Peptide Bioregulator for Urological Research
Vesilute is a Khavinson tetrapeptide bioregulator targeting bladder and urological tissue, normalizing gene expression in urothelial cells to support bladder function and urinary tract health.
Bladder Tissue Peptide Bioregulator for Urological Research
Bladder tissue-specific peptide bioregulator supporting urothelial gene expression normalization for bladder health and urological research.
As one of the most studied compounds in the recovery & healing research space, Vesilute has attracted sustained scientific interest across Urological research, Bladder health studies. Peer-reviewed evidence indicates that bladder-specific Khavinson bioregulator, which has positioned Vesilute as a reference standard for researchers exploring urological research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Vesilute Documented Benefits: 1 Documented Mechanisms
Bladder Tissue Support
Normalizes urothelial cell gene expression for bladder function and health.
How Vesilute Works: Molecular Mechanism & Pathway
Short peptide with urological tissue specificity for epigenetic gene expression modulation in urothelial cells.
The 1 primary research pathways identified for Vesilute — Bladder Tissue Support — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that urological tissue gene expression support, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Vesilute's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Vesilute is routinely studied alongside VIP and Oxytocin in recovery & healing-focused compound panels. Researchers investigating urological research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that 20mg research format has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Vesilute research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Bladder-specific Khavinson bioregulator
- Urological tissue gene expression support
- 20mg research format
Ideal For
- Urological research
- Bladder health studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Vesilute. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Bladder-specific Khavinson bioregulator
Urological tissue gene expression support
20mg research format
Third-Party Verified Every Batch
Each vial of Vesilute is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
